Concepedia

Author

Gabriel Mak

Sarah Cannon Research Institute

Also Known As

G Mak, G. Mak, Gabriel Mak, Gabriel W. H. Mak, Gerald Mak

32

Publications

438

Citations

12

H-Index

10

Concepts

All Affiliations

Sarah Cannon Research InstituteUniversity College LondonAstraZeneca (Japan)Newcastle UniversityShizuoka Cancer Center
GM

About

Gabriel Mak is an author at Sarah Cannon Research Institute specializing in radiation oncology, oncology, and cancer therapeutics.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

32

2

Cancer Therapeutics

2

2

32

3

Pathology

1

1

20

4

Pharmacology

1

1

12

5

Surgical Oncology

1

1

20

Gabriel Mak

×

12

Publications

351

Citations

11

H-Index

YearCitations

A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumours

Gabriel Mak, Jean‐Charles Soria, Sarah P. Blagden,

British Journal of Cancer

2019

99

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade

Michele Moschetta, Mario Uccello, Benjamin Kasenda,

BioMed Research International

2017

65

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study

Suresh Senan, Isamu Okamoto, Gyeong‐Won Lee,

Clinical Lung Cancer

2019

64

Early clinical efficacy of TAS-120, a covalently bound FGFR inhibitor, in patients with cholangiocarcinoma

Lipika Goyal, Hendrik-Tobias Arkenau, Ben Tran,

Annals of Oncology

2017

20

Cutaneous metastasis of prostate carcinoma treated with radiotherapy: a case presentation

Gabriel Mak, Melvin Chin, Najmun Nahar,

BMC Research Notes

2014

16

The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study

Emily He, Nicholas J. Hawkins, Gabriel Mak,

The Oncologist

2016

15

Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with <i>BRAF</i> V600–mutant tumours

Noelia Nebot, Hendrik‐Tobias Arkenau, Jeffrey R. Infante,

British Journal of Clinical Pharmacology

2017

14

Dabrafenib and trametinib activity in a patient with BRAF V600E mutated and microsatellite instability high (MSI-H) metastatic endometrial cancer

Michele Moschetta, Gabriel Mak, Joana Hauser,

Experimental Hematology and Oncology

2017

13

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Hendrik‐Tobias Arkenau, Antoîne Italiano, Gabriel Mak,

European Journal of Cancer

2018

12

OA05.06 Datopotamab Deruxtecan (Dato-DXd) + Durvalumab ± Carboplatin in Advanced/mNSCLC: Initial Results from Phase 1b TROPION-Lung04

K. Papadopoulos, Débora S. Bruno, Satoru Kitazono,

Journal of Thoracic Oncology

2023

12

Page 1